CClinicalTrials.gg
CompletedNCT07150390Updated Sep 2, 2025

Aetiologies and Prognosis of Small Bowel Obstruction in Virgin Abdomen

An observational study in Small Bowel Obstruction and Small Bowel Obstruction Adhesion, sponsored by The First Affiliated Hospital with Nanjing Medical University. Completed at 1 site in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
312
Ages
14 Years and older
Sex
All
01

Study summary

Small bowel obstruction (SBO) is a surgical emergency in which the passage of intestinal contents is prevented due to mechanical obstruction of small intestine. It accounts for almost 50% of all emergency laparotomies with significant in-hospital morbidity and costs. SBO has known to occur in patients who had no prior abdominal surgery, referring to as a virgin abdomen (VA). Nowadays, non-operative management comprising of bowel decompression, water-soluble contrast agents, and fluid resuscitation have been found safe and efficacious in 70% of SBOs caused by adhesions (ASBO). However, based on the assumption that SBO in the virgin abdomen (SBO-VA) is usually caused by other aetiologies than adhesions, such as malignancy and hernias, many authors suggest that surgical exploration is still mandatory. Besides, recent studies do show high incidence of adhesions also in patients with SBO-VA. This observation signifies that guideline on the management of ASBO might also apply to the majority of patients with SBO-VA. Hence, the aim of our retrospectively study is to shed light on the aetiologies of SBO-VA. We believe treatment strategy needs to be based on the underlying reasons of obstructions and conditions of the patients and evaluate their prognosis accordingly.

02

Conditions studied

  • Small Bowel Obstruction
  • Small Bowel Obstruction Adhesion
03

In context

Lead sponsor

The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 543 studies on the registry; 301 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

From January 2009 to December 2020, 2098 consecutive patients with 2275 admissions who diagnosed with bowel obstuction were enrolled in the First Affiliated Hospital of Nanjing Medical University, P. R. China. For patients with multiple admissions, only the index admissions were included, the rest were used for follow-up analysis. The detailed medical records of those 2098 patients were collected and reviewed. Only patients without prior abdominal operations and with CT or surgical exploration confirmation of the diagnosis of SBO were included. In addition, patients with age less than 14 years were excluded in this study. The diagnosis of SBO was established if an attending surgeon documented interpretation of CT imaging and was in agreement with the diagnosis. Finally, 312 patients with SBO in virgin abdomen were included in this study.

Inclusion criteria

  • Only patients without prior abdominal operations and with CT or surgical exploration confirmation of the diagnosis of SBO were included.

Exclusion criteria

Exclusion Criteria:

  • Patients with age less than 14 years were excluded in this study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
312 participants (actual)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • SBO-VA

    small intestinal obstruction patients without a history of abdominal surgery (virgin abdomen)

06

What researchers measure

Primary outcomes

  1. The recurrence rate within 5 years after discharge

    The recurrence rate of small bowel obstruction within 5 years after discharge

    Time frame: 5 years

07

Study locations

1 site
  • The First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 230020, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07150390
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Responsible party
Xiaochun Ping (Associate Chief Physician, The First Affiliated Hospital with Nanjing Medical University) — Principal investigator
First posted
Sep 2, 2025
Start date
Jan 1, 2022
Primary completion
Aug 1, 2023
Completion
Sep 1, 2023
Last update
Sep 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion